Logo image of KZR

KEZAR LIFE SCIENCES INC (KZR) Stock Fundamental Analysis

NASDAQ:KZR - Nasdaq - US49372L2097 - Common Stock - Currency: USD

6.18  +0.13 (+2.15%)

After market: 6.18 0 (0%)

Fundamental Rating

2

Overall KZR gets a fundamental rating of 2 out of 10. We evaluated KZR against 571 industry peers in the Biotechnology industry. While KZR seems to be doing ok healthwise, there are quite some concerns on its profitability. KZR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KZR had negative earnings in the past year.
In the past year KZR has reported a negative cash flow from operations.
KZR had negative earnings in each of the past 5 years.
KZR had a negative operating cash flow in each of the past 5 years.
KZR Yearly Net Income VS EBIT VS OCF VS FCFKZR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of KZR (-62.08%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -75.99%, KZR is in line with its industry, outperforming 54.19% of the companies in the same industry.
Industry RankSector Rank
ROA -62.08%
ROE -75.99%
ROIC N/A
ROA(3y)-31.3%
ROA(5y)-32.12%
ROE(3y)-35.78%
ROE(5y)-36.39%
ROIC(3y)N/A
ROIC(5y)N/A
KZR Yearly ROA, ROE, ROICKZR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

KZR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZR Yearly Profit, Operating, Gross MarginsKZR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

KZR does not have a ROIC to compare to the WACC, probably because it is not profitable.
KZR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, KZR has less shares outstanding
KZR has a worse debt/assets ratio than last year.
KZR Yearly Shares OutstandingKZR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
KZR Yearly Total Debt VS Total AssetsKZR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -3.73, we must say that KZR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.73, KZR is in line with its industry, outperforming 43.49% of the companies in the same industry.
KZR has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of KZR (0.08) is worse than 65.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -3.73
ROIC/WACCN/A
WACC10.41%
KZR Yearly LT Debt VS Equity VS FCFKZR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 7.65 indicates that KZR has no problem at all paying its short term obligations.
The Current ratio of KZR (7.65) is better than 71.12% of its industry peers.
KZR has a Quick Ratio of 7.65. This indicates that KZR is financially healthy and has no problem in meeting its short term obligations.
KZR's Quick ratio of 7.65 is fine compared to the rest of the industry. KZR outperforms 71.48% of its industry peers.
Industry RankSector Rank
Current Ratio 7.65
Quick Ratio 7.65
KZR Yearly Current Assets VS Current LiabilitesKZR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

KZR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -631.15%.
EPS 1Y (TTM)-631.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-768.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

KZR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.65% yearly.
KZR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.75% yearly.
EPS Next Y-337.47%
EPS Next 2Y-158.23%
EPS Next 3Y-73.55%
EPS Next 5Y-16.65%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y2.75%

3.3 Evolution

KZR Yearly Revenue VS EstimatesKZR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
KZR Yearly EPS VS EstimatesKZR Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KZR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZR Price Earnings VS Forward Price EarningsKZR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZR Per share dataKZR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

A cheap valuation may be justified as KZR's earnings are expected to decrease with -73.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-158.23%
EPS Next 3Y-73.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KZR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEZAR LIFE SCIENCES INC

NASDAQ:KZR (2/24/2025, 8:00:03 PM)

After market: 6.18 0 (0%)

6.18

+0.13 (+2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-12 2025-03-12/amc
Inst Owners55.02%
Inst Owner Change-99.86%
Ins Owners2.59%
Ins Owner Change0%
Market Cap45.11M
Analysts74
Price Target13.77 (122.82%)
Short Float %1.25%
Short Ratio1.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.59%
Min EPS beat(2)12.62%
Max EPS beat(2)16.56%
EPS beat(4)3
Avg EPS beat(4)6.31%
Min EPS beat(4)-14.7%
Max EPS beat(4)16.56%
EPS beat(8)5
Avg EPS beat(8)4.17%
EPS beat(12)9
Avg EPS beat(12)6.43%
EPS beat(16)11
Avg EPS beat(16)4.83%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.95%
EPS NQ rev (1m)-5.42%
EPS NQ rev (3m)0.35%
EPS NY rev (1m)0%
EPS NY rev (3m)50.21%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.44
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-8.92
EYN/A
EPS(NY)-9.4
Fwd EYN/A
FCF(TTM)-10.46
FCFYN/A
OCF(TTM)-10.46
OCFYN/A
SpS0.96
BVpS18.36
TBVpS18.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.08%
ROE -75.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.3%
ROA(5y)-32.12%
ROE(3y)-35.78%
ROE(5y)-36.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.7%
Cap/Sales 0.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.65
Quick Ratio 7.65
Altman-Z -3.73
F-Score3
WACC10.41%
ROIC/WACCN/A
Cap/Depr(3y)115.3%
Cap/Depr(5y)81.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-631.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-768.75%
EPS Next Y-337.47%
EPS Next 2Y-158.23%
EPS Next 3Y-73.55%
EPS Next 5Y-16.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y2.75%
EBIT growth 1Y-47.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.31%
OCF growth 3YN/A
OCF growth 5YN/A